Ono Pharmaceutical

Close up shot of the target from a dart game
Biotech

Ono's BMS-partnered IO drug passes phase 2 gastric cancer test

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.
James Waldron Oct 9, 2025 10:10am
team layoffs workforce

Ono Pharma lays off 83 staffers at Cambridge site

Apr 29, 2025 1:56pm
An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Mar 12, 2025 6:30am
An imaginary winners podium is modelled and rendered

Merck KGaA tumor trial hits goal, teeing up Daiichi, Ono rivalry

Nov 12, 2024 4:46am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Ono inks $700M biobuck deal to bag preclinical LigaChem ADC

Oct 10, 2024 9:40am
pivot change turnaround direction walk away

Shattuck axes CD47 program, cuts 40% of staff over weak data

Oct 1, 2024 8:22am